CIMERLI
CIMERLI (ranibizumab-eqrn) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of several retinal diseases. It is used in patients with neovascular (wet) age-related macular degeneration, diabetic retinopathy, and diabetic macular edema. Additionally, the therapy is approved to treat macular edema following retinal vein occlusion and myopic choroidal neovascularization. These conditions are characterized by ocular angiogenesis and vascular leakage that contribute to disease pathophysiology.
How CIMERLI Works
Ranibizumab-eqrn works by binding to the receptor binding site of active forms of vascular endothelial growth factor A (VEGF-A). This binding prevents VEGF-A from interacting with its receptors, VEGFR1 and VEGFR2, on the surface of endothelial cells. By inhibiting this interaction, the drug reduces endothelial cell proliferation, the formation of new blood vessels, and vascular leakage. This mechanism targets the underlying processes that cause neovascularization and edema in the eye.
Details
- Status
- Prescription
- First Approved
- 2022-08-02
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CIMERLI Approval History
What CIMERLI Treats
5 indicationsCIMERLI is approved for 5 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema Following Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
- Myopic Choroidal Neovascularization
CIMERLI Competitors
Pro6 other drugs also target VEGF. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGF). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to CIMERLI
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CIMERLI FDA Label Details
ProIndications & Usage
FDA Label (PDF)CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: • Neovascular (Wet) Age-Related Macular Degeneration (AMD) • Macular Edema Following Retinal Vein Occlusion (RVO) • Diabetic Macular Edema (DME) • Diabetic Retinopathy (DR) • Myopic Choroidal Neovascularization (mCNV) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascula...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.